Skip to main content
. 2015 Jan 23;6:6153. doi: 10.1038/ncomms7153

Figure 6. UCHL1 is a good prognostic marker.

Figure 6

(ac) Human breast tumour sections (30 samples) were stained with anti-UCHL1 (a) and anti-HIF-1α (b) antibodies (scale bar, 50 μm). (c) A PrognoScan database-based Kaplan–Meier analysis of the overall survival of 158 breast cancer patients stratified by high (red) and low (blue) UCHL1 levels (high: n=23, low: n=135; log-rank tests P<0.05). (dg) Microarrays spotted with human lung tumour tissues (254 samples) were stained with anti-UCHL1 (d) and anti-HIF-1α (e) antibodies (scale bar, 500 μm). A Kaplan–Meier analysis of the overall survival of the 254 lung cancer patients stratified by high (red; +++ and ++ in d,e) and low (blue;+and −in d,e) UCHL1 (f) and HIF-1α (g) levels (log-rank tests, P<0.05).

HHS Vulnerability Disclosure